Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19061831 | METHODS OF TREATING INFLAMMATORY ARTHRITIS USING IL-17 ANTAGONISTS | February 2025 | January 2026 | Allow | 11 | 2 | 1 | Yes | No |
| 18983037 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983034 | METHODS OF TREATING PSORIASIS WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18983030 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASE WITH SECUKINUMAB | December 2024 | December 2025 | Allow | 12 | 2 | 1 | Yes | No |
| 18733339 | ORTHOGONAL IL-21 RECEPTOR/CYTOKINE SYSTEMS | June 2024 | July 2025 | Allow | 13 | 1 | 1 | Yes | No |
| 18610618 | ANTI-GIANT PANDA LIF MONOCLONAL ANTIBODY, and HYBRIDOMA CELL LINE, AND USE THEREOF | March 2024 | November 2024 | Allow | 7 | 1 | 0 | Yes | No |
| 18414813 | PROTEASE-ACTIVATED CYTOKINE | January 2024 | July 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18514330 | IL12RB1-BINDING MOLECULES AND METHODS OF USE | November 2023 | February 2025 | Abandon | 15 | 1 | 1 | No | No |
| 18280100 | Methods Of Treating Anemia in Myelodysplastic Syndromes | September 2023 | June 2025 | Allow | 22 | 2 | 1 | Yes | Yes |
| 18457427 | Agonistic Interleiukin 15 Complexes and Uses Thereof | August 2023 | May 2025 | Abandon | 20 | 2 | 1 | Yes | Yes |
| 18019081 | IFNGR1 BINDING MOLECULES AND METHODS OF USE | January 2023 | November 2024 | Abandon | 21 | 2 | 1 | Yes | No |
| 18018837 | IL10RB Binding Molecules and Encoding Nucleic Acids | January 2023 | December 2024 | Allow | 23 | 2 | 2 | Yes | No |
| 18055362 | ANTIBODIES CAPABLE OF BINDING TO CD27, VARIANTS THEREOF AND USES THEREOF | November 2022 | November 2024 | Abandon | 24 | 2 | 0 | No | Yes |
| 17817965 | Antibodies Against IL-1 Beta | August 2022 | September 2025 | Abandon | 38 | 1 | 0 | Yes | No |
| 17845386 | ANTI-INTERLEUKIN-23 P19 ANTIBODIES AND METHODS OF USE THEREOF | June 2022 | March 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17682781 | Methods of Treating Glioblastoma | February 2022 | January 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17638372 | Anti-IL31 Antibodies for Veterinary Use | February 2022 | March 2026 | Allow | 48 | 1 | 1 | Yes | No |
| 17570954 | ANTIBODY HEAVY CHAIN CONSTANT DOMAINS | January 2022 | January 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17647082 | POLYNUCLEOTIDES ENCODING ANTIBODIES THAT SPECIFICALLY BIND TO HUMAN IL-15 | January 2022 | May 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17620026 | IL-23 and TNF-alpha binding Bi-specific Heavy Chain Polypeptides | December 2021 | October 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17545894 | METHODS OF TREATING INFLAMMATORY ARTHRITIS USING SECUKINUMAB | December 2021 | June 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17531914 | VACCINE COMPOSITION COMPRISING A MUTANT OF HUMAN INTERLEUKIN-15 | November 2021 | March 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17530727 | NUCLEIC ACIDS ENCODING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP | November 2021 | April 2025 | Allow | 40 | 2 | 0 | Yes | No |
| 17530850 | METHODS OF TREATMENT UTILIZING POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP | November 2021 | August 2025 | Allow | 45 | 3 | 0 | Yes | No |
| 17388129 | INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS | July 2021 | November 2024 | Allow | 40 | 1 | 1 | Yes | No |
| 17385284 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | July 2021 | April 2025 | Allow | 45 | 4 | 0 | Yes | Yes |
| 17373866 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | July 2021 | June 2025 | Abandon | 47 | 4 | 1 | No | Yes |
| 17339858 | METHODS FOR TREATING ACTIVE EOSINOPHILIC ESOPHAGITIS | June 2021 | January 2026 | Abandon | 55 | 1 | 1 | No | No |
| 17296036 | An Interleukin 21 Protein (IL21) Mutant and Encoding Nucleic Acid | May 2021 | January 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17294157 | ANTI-CANCER MONOTHERAPY USING SA-4-1BBL | May 2021 | December 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17313463 | Diagnoses of susceptibility to cystitis through detection of reduced ASC expression or activity | May 2021 | September 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17221218 | ANTIBODIES THAT BIND INTERLEUKIN-10 RECEPTOR-2 PEPTIDES, COMPOSITIONS, AND METHODS OF USE THEREOF | April 2021 | December 2024 | Allow | 45 | 2 | 1 | Yes | Yes |
| 17195757 | METHODS FOR TREATING HEPCIDIN-MEDIATED DISORDERS | March 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17192183 | COMPOSITIONS COMPRISING AN INTERLEUKIN CONSTRUCT | March 2021 | December 2024 | Abandon | 46 | 2 | 1 | No | No |
| 17270795 | MASKED CYTOKINE CONJUGATES | February 2021 | September 2025 | Abandon | 54 | 1 | 1 | No | No |
| 17164384 | Method of Treating Psoriasis with Anti-IL23 Specific Antibody | February 2021 | April 2025 | Abandon | 51 | 3 | 0 | No | Yes |
| 17163961 | METHODS OF TREATMENT OF IL-17A ASSOCIATED CONDITIONS | February 2021 | September 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17105181 | MULTISPECIFIC ANTIBODIES | November 2020 | November 2025 | Abandon | 59 | 2 | 1 | No | Yes |
| 16981915 | METHODS OF TREATING ULCERATIVE COLITIS WITH AN ANTI-IL-23p19 ANTIBODY | September 2020 | August 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16992628 | Safe and Effective Method of Treating Psoriasis with Anti-IL23 Specific Antibody | August 2020 | December 2024 | Abandon | 52 | 4 | 1 | No | Yes |
| 16988460 | Method of producing th9 t-cells | August 2020 | August 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16771132 | METHODS AND MATERIALS FOR THE DETECTION OF LATENT TUBERCULOSIS INFECTION | June 2020 | May 2025 | Abandon | 59 | 5 | 1 | No | No |
| 16639514 | METHODS FOR TREATING ALCOHOL-INDUCED BRAIN INJURY AND REDUCING ALCOHOL ADDICTION | February 2020 | July 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16752040 | COMPOSITIONS AND METHODS FOR STIMULATING NATURAL KILLER CELLS | January 2020 | June 2025 | Allow | 60 | 4 | 2 | Yes | No |
| 16607154 | MULTISPECIFIC MOLECULES COMPRISING A NON-IMMUNOGLOBULIN HETERODIMERIZATION DOMAIN AND USES THEREOF | October 2019 | February 2025 | Abandon | 60 | 4 | 1 | No | No |
| 16595845 | INTERLEUKIN-2 IMMUNOCONJUGATE, A CD40 AGONIST, AND OPTIONALLY A PD-1 AXIS BINDING ANTAGONIST FOR USE IN METHODS OF TREATING CANCER | October 2019 | June 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 16603040 | PEPTIDES INHIBITING GAMMA-c-CYTOKINE ACTIVITY AND METHODS OF USE | October 2019 | December 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16507126 | TREATMENT OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ANTAGONISM OF THE IL-20R | July 2019 | March 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 15448406 | METHOD FOR TREATING ANTIBODY-MEDIATED REJECTION POST-TRANSPLANTATION | March 2017 | May 2025 | Abandon | 60 | 12 | 1 | Yes | No |
| 15317788 | EXPANSION OF LYMPHOCYTES WITH A CYTOKINE COMPOSITION FOR ACTIVE CELLULAR IMMUNOTHERAPY | December 2016 | March 2022 | Abandon | 60 | 8 | 1 | Yes | Yes |
| 15254190 | ANTI-IL-17 ANTIBODIES | September 2016 | June 2019 | Allow | 33 | 2 | 1 | Yes | No |
| 14897344 | IL-15 Mutant Polypeptides As IL-15 Antagonists and Encoding Nucleic Acids | December 2015 | September 2018 | Allow | 33 | 1 | 1 | Yes | No |
| 14894945 | IL-1beta-IL-1Ra CHIMERA AND METHODS OF USING THE SAME | November 2015 | October 2017 | Allow | 22 | 1 | 1 | Yes | No |
| 14921455 | Methods of Treating a Neoplastic Disease | October 2015 | February 2019 | Allow | 40 | 2 | 1 | Yes | Yes |
| 14651946 | Solution Formulations of Engineered Anti-IL-23p19 Antibodies | June 2015 | July 2020 | Abandon | 60 | 12 | 1 | Yes | Yes |
| 14649526 | IL-33R and IL-1RAcP Fusion Proteins | June 2015 | May 2020 | Allow | 60 | 7 | 1 | Yes | No |
| 14491641 | ANTIBODIES DIRECTED TO IL-17A/IL-17F HETERODIMERS | September 2014 | January 2018 | Allow | 40 | 2 | 1 | Yes | Yes |
| 13992814 | Compositions Comprising IL-7 Receptor Ligands | August 2013 | July 2015 | Allow | 25 | 2 | 1 | Yes | No |
| 13933594 | CELLS EXPRESSING ANTI-GD2 ANTIBODIES AND METHODS RELATED THERETO | July 2013 | October 2014 | Allow | 15 | 1 | 1 | Yes | No |
| 13765625 | ANTIBODIES TO HEPATOCYTE GROWTH FACTOR ACTIVATOR | February 2013 | October 2014 | Allow | 20 | 0 | 0 | Yes | No |
| 13810474 | ANTI-IL-23 HETERODIMER SPECIFIC ANTIBODIES | January 2013 | May 2015 | Allow | 28 | 1 | 1 | Yes | No |
| 13729645 | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-13 AND IL-17 | December 2012 | April 2015 | Allow | 28 | 0 | 1 | Yes | No |
| 13709055 | Neutralising Antibody Molecules Having Specificity for Human IL-17 | December 2012 | June 2014 | Allow | 18 | 1 | 0 | Yes | No |
| 13671371 | NUCLEIC ACIDS ENCODING ENGINEERED ANTI-IL-23R ANTIBODIES | November 2012 | December 2013 | Allow | 13 | 1 | 1 | Yes | No |
| 13392783 | IL-17 BINDING COMPOUNDS AND MEDICAL USES THEREOF | September 2012 | February 2016 | Allow | 47 | 3 | 1 | Yes | No |
| 13593057 | ANTI-GD2 ANTIBODIES | August 2012 | February 2013 | Allow | 6 | 0 | 1 | Yes | No |
| 13589984 | METHODS OF TREATMENT USING IL-18 RECEPTOR ANTIGEN BINDING PROTEINS | August 2012 | April 2013 | Allow | 8 | 0 | 1 | Yes | No |
| 13492280 | METHODS OF TREATMENT USING ANTI-IL-17A/IL-17F CROSS-REACTIVE ANTIBODIES | June 2012 | September 2013 | Allow | 15 | 1 | 1 | Yes | No |
| 13409585 | METHODS OF TREATMENT USING ANTI-IL-17F ANTIBODIES | March 2012 | August 2013 | Allow | 17 | 1 | 2 | Yes | No |
| 13399847 | ENGINEERED ANTI-IL-23R ANTIBODIES | February 2012 | July 2012 | Allow | 5 | 0 | 1 | Yes | No |
| 13349380 | METHODS OF PRODUCING ANTI-IL-22RA ANTIBODIES | January 2012 | April 2013 | Allow | 15 | 2 | 1 | Yes | No |
| 13339110 | ANTI-IL-17A/IL-17F CROSS-REACTIVE ANTIBODIES | December 2011 | August 2013 | Allow | 20 | 2 | 1 | Yes | No |
| 13330902 | BINDING COMPOUNDS FOR IL-27 | December 2011 | November 2013 | Allow | 23 | 4 | 1 | Yes | No |
| 13242429 | DNA Encoding Antibody Molecules Which Bind Human IL-17 | September 2011 | January 2013 | Allow | 16 | 2 | 0 | Yes | No |
| 13058914 | ANTI-IL-12/IL-23 ANTIBODIES | July 2011 | June 2013 | Allow | 28 | 1 | 1 | Yes | No |
| 13120855 | PEPTIDE ANTAGONIST OF INTERLEUKIN-15 ACTIVITY | June 2011 | January 2013 | Allow | 22 | 1 | 1 | Yes | No |
| 13025002 | IL-D80 POLYNUCLEOTIDES | February 2011 | August 2011 | Allow | 6 | 0 | 1 | Yes | No |
| 13001084 | ANTAGONISTS OF IL-6 | February 2011 | September 2013 | Allow | 32 | 2 | 1 | Yes | No |
| 12978115 | IL-15 MUTANTS HAVING ANTAGONIST ACTIVITY | December 2010 | June 2016 | Allow | 60 | 3 | 1 | Yes | No |
| 12745139 | METHODS FOR TREATING ALLERGIC AIRWAY INFLAMMATION, AIRWAY HYPERSENSITIVITY, AND EOSINOPHILIA | November 2010 | January 2013 | Allow | 32 | 2 | 1 | No | Yes |
| 12900870 | METHOD FOR SCREENING INHIBITORS OF INTERLEUKIN-32 (IL-32) | October 2010 | March 2015 | Allow | 53 | 1 | 1 | Yes | No |
| 12883033 | ANTIBODY MODULATORS OF HEPATOCYTE GROWTH FACTOR ACTIVATOR | September 2010 | November 2012 | Allow | 26 | 1 | 1 | Yes | No |
| 12670112 | IL-18 RECEPTOR ANTIGEN BINDING PROTEINS | August 2010 | December 2011 | Allow | 23 | 0 | 1 | Yes | No |
| 12829697 | USE OF ANTI-IL-20 ANTIBODY FOR TREATING RHEUMATOID ARTHRITIS | July 2010 | April 2012 | Allow | 21 | 1 | 0 | No | No |
| 12788129 | METHODS OF TREATMENT USING ANTIBODIES TO IL-17 HOMOLOGOUS POLYPEPTIDES | May 2010 | August 2011 | Allow | 14 | 1 | 0 | No | No |
| 12774188 | ANTI-IL-17F ANTIBODIES | May 2010 | June 2011 | Allow | 13 | 0 | 1 | Yes | No |
| 12716993 | HOST CELLS EXPRESSING IL-18 RECEPTORS | March 2010 | June 2011 | Allow | 15 | 1 | 0 | No | No |
| 12526544 | ENGINEERED ANTI-IL-23R ANTIBODIES | February 2010 | October 2011 | Allow | 26 | 1 | 1 | Yes | No |
| 12618178 | KIT COMPRISING AN ANTIBODY TO INTERLEUKIN 17 RECEPTOR-LIKE PROTEIN | November 2009 | October 2011 | Allow | 23 | 2 | 1 | No | No |
| 12616476 | NUCLEIC ACIDS ENCODING MURINE IL-174 | November 2009 | November 2010 | Allow | 12 | 0 | 1 | Yes | No |
| 12599484 | Methods of Immunoregulation by Albumin Neo-Structures | November 2009 | April 2015 | Allow | 60 | 4 | 1 | Yes | No |
| 12306251 | ANTIBODY MOLECULES WHICH BIND TO HUMAN IL-17 | October 2009 | September 2011 | Allow | 32 | 2 | 1 | No | No |
| 12604289 | METHODS OF TREATING INFLAMMATORY DISORDERS OF THE LUNGS | October 2009 | May 2011 | Allow | 19 | 1 | 0 | Yes | No |
| 12586893 | ANTIBODIES AGAINST HUMAN IL17 AND USES THEREOF | September 2009 | April 2011 | Allow | 18 | 1 | 1 | Yes | No |
| 12565554 | INTERLEUKIN-17 RECEPTOR HOMOLOGUE | September 2009 | November 2010 | Allow | 14 | 0 | 0 | No | No |
| 12549497 | PHARMACEUTICAL COMPOSITIONS, KITS, AND THERAPEUTIC USES OF ANTAGONIST ANTIBODIES TO IL- 17E. | August 2009 | June 2011 | Allow | 21 | 2 | 0 | Yes | No |
| 12511756 | ANTIBODIES AGAINST INTERLEUKIN-18 BINDING PROTEIN, THEIR PREPARATION AND USE | July 2009 | January 2013 | Allow | 41 | 3 | 1 | Yes | No |
| 12496197 | IL-1 RELATED POLYPEPTIDES | July 2009 | January 2011 | Allow | 19 | 1 | 0 | No | No |
| 12494631 | POLYNUCLEOTIDES ENCODING ANTI-GD2 ANTIBODIES | June 2009 | May 2012 | Allow | 35 | 2 | 1 | Yes | No |
| 12495633 | ANTIBODIES BINDING IL-1 RELATED POLYPEPTIDES | June 2009 | August 2013 | Allow | 50 | 2 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner JIANG, DONG.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner JIANG, DONG works in Art Unit 1674 and has examined 163 patent applications in our dataset. With an allowance rate of 89.6%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 36 months.
Examiner JIANG, DONG's allowance rate of 89.6% places them in the 72% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by JIANG, DONG receive 2.04 office actions before reaching final disposition. This places the examiner in the 53% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by JIANG, DONG is 36 months. This places the examiner in the 35% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +9.2% benefit to allowance rate for applications examined by JIANG, DONG. This interview benefit is in the 41% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 34% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 52.5% of cases where such amendments are filed. This entry rate is in the 78% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 71.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 53.8% are granted (fully or in part). This grant rate is in the 54% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 32.5% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.7% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.